Brought to you by 
Takeda expands European presence through DSP lurasidone deal; deal terminated
08 May 2015
Executive Summary
Adding another compound to its already-strong CNS pipeline, Takeda Pharmaceutical Co. Ltd. has licensed rights to co-develop and commercialize Dainippon Sumitomo Pharma Co. Ltd.’s (DSP) lurasidone for schizophrenia and bipolar disorder. Takeda’s rights cover 26 member states of the European Union, excluding the UK (where DSP retains rights), Switzerland, Norway, Turkey, and Russia.
Deal Industry
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Takeda expands European presence through DSP lurasidone deal; deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice